ClinicalTrials.gg
TerminatedNCT03536013Updated Jul 1, 2024

Efficacy of a Full-Thickness Placental Allograft in Lumbar Microdiscectomy

An interventional study of Other: Full-thickness placental allograft in Surgical Wound and Herniation, sponsored by StimLabs. Terminated at 1 site in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-01.

Sponsored by StimLabs · Not applicable, Interventional, and Treatment

Why this study was terminated
Low enrollment.
Phase
Not applicable
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

To evaluate the efficacy of full thickness placental allograft use in Microdiscectomy application. To evaluate post-microdiscectomy reherniation rate in patients treated with full-thickness placental allografts.

Read the detailed description

The primary objective is to evaluate the efficacy of full thickness placental allograft use in improving back and leg pain, when applied to patients undergoing lumbar microdiscectomy.

02

Conditions studied

  • Surgical Wound
  • Herniation
03

In context

Surgical Wound

315 studies on the registry are indexed under Surgical Wound; 57 are open to participants now.

This study's enrollment of 27 is below the median of 66 across 242 interventional studies indexed under Surgical Wound.

Browse Surgical Wound studies →

Lead sponsor

StimLabs is the lead sponsor of 8 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ambulatory with radiating low back and leg pain for greater than 6 months prior to surgery with clinical diagnosis of lumbar protruding disc.
  • Consent and compliance with all aspects of the study protocol, methods, providing data during follow-up contact.

Exclusion criteria

Exclusion Criteria:

  • Severe hypertension systolic blood pressure (greater than or equal to 200 mm -Hg or diastolic blood pressure greater than or equal to 182 mm Hg)
  • greater than 45 kg/m2
  • Subject has had major surgery at the index level
  • Is an active smoker or stopped smoking in the last 6 months
  • Any pain that could interfere with the assessment of index level pain (e.g. pain in any other part of the spine)
  • Active rheumatoid arthritis
  • Active, local or systemic such as lung cancer or leukemia
  • History of vascular disease or sickle cell anemia
  • Use of the following medications:

No significant anticoagulant therapy (e.g. Heparin or Lovenox) during the study (treatment such as Aspirin and Plavix are allowed)

  • No systemic treatments that may interfere with safety or efficacy assessments during the study
  • No
  • No use of

    • Subject is pregnant or plans to become pregnant within 24 months of treatment
    • Subject does not provide full consent
    • Personal injury, workman's compensation or other legally-related treatment patients.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Treatment

    91 patients will undergo a typical lumbar microdiscectomy with the addition of a full-thickness placental allograft after the microdiscectomy has been performed.

    Other: Other: Full-thickness placental allograft

  • No intervention
    Control

    91 patients will undergo a typical lumbar microdiscectomy without the addition of a full-thickness placental allograft.

Interventions

  • OtherOther: Full-thickness placental allograft

    A full-thickness placental allograft will be applied to the annulus of the index lumbar level prior to site closure.

06

What researchers measure

Primary outcomes

  1. Measuring efficacy of full-thickness placental allograft in reducing back and leg pain post-microdiscectomy.

    Oswestry Disability Index (ODI)

    Time frame: 24 months

  2. Measuring efficacy of full-thickness placental allograft in reducing back and leg pain post-microdiscectomy.

    12-Item Short Form Survey (SF12)

    Time frame: 24 months

Secondary outcomes

  1. Evaluation of post-microdiscectomy reherniation rate.

    Reherniation rates will be compared between the experimental and control groups.

    Time frame: 24 month

07

Study locations

1 site
  • Polaris Spine and Neurosurgery
    Atlanta, Georgia 30328, United States
08

References and documents

Individual participant data

Plan to share: No — The sponsor will not have access to personally identifying participant information.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03536013
Lead sponsor
StimLabs
Responsible party
Sponsor
First posted
May 24, 2018
Start date
May 3, 2018
Primary completion
Aug 1, 2019
Completion
Aug 1, 2019
Last update
Jul 1, 2024

Study contacts

Thomas Morrison, M.D.
principal investigator · Polaris Spine and Neurosurgery

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion